Compare Core Scientific Inc (CORZ) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Core Scientific Inc vs Gilead Sciences, Inc. — how do they compare? Core Scientific Inc trades at $15.28 (market cap $4.94B), while Gilead Sciences, Inc. trades at $147.95 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 36.9× Core Scientific Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Core Scientific Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Core Scientific Inc for 20 Days and Gilead Sciences, Inc. for 111 Days on average.
| CORZ | GILD | |
|---|---|---|
Market Cap | $4.94B | $182.40B |
Volume | 15,630,800 | 4,469,821 |
Sector | Technology | Health |
52-Week High | $29.16 | $155.80 |
52-Week Low | $13.57 | $116.74 |
Typical Hold Time | 20 Days | 111 Days |
Enterprise Value | $7.46B | $205.46B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CORZ trades at $15.94, down 4.44% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $288.62 million in 2025, with a negative net income margin of -324.9% in 2026. Recent news highlights its pivot to AI data center hosting and executive appointments, while analyst consensus remains strongly bullish with an 86.36% buy rating.
The outlook is mixed: strong analyst support and AI infrastructure growth offer upside potential, but persistent losses, high cash burn, and competitive pressures pose significant risks. Investors face volatility from execution challenges in the capital-intensive data center transition.
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Core Scientific Inc
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
